254 related articles for article (PubMed ID: 24292030)
1. Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children.
Apa H; Devrim İ; Bayram N; Deveci R; Demir-Özek G; Cartı ÖU
Turk J Pediatr; 2013; 55(4):378-83. PubMed ID: 24292030
[TBL] [Abstract][Full Text] [Related]
2. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of visceral leishmaniasis in children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
[TBL] [Abstract][Full Text] [Related]
4. Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
Morizot G; Jouffroy R; Faye A; Chabert P; Belhouari K; Calin R; Charlier C; Miailhes P; Siriez JY; Mouri O; Yera H; Gilquin J; Tubiana R; Lanternier F; Mamzer MF; Legendre C; Peyramond D; Caumes E; Lortholary O; Buffet P
PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004304. PubMed ID: 26735920
[TBL] [Abstract][Full Text] [Related]
5. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis.
Santos MA; Marques RC; Farias CA; Vasconcelos DM; Stewart JM; Costa DL; Costa CH
Rev Soc Bras Med Trop; 2002; 35(6):629-33. PubMed ID: 12612746
[TBL] [Abstract][Full Text] [Related]
6. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
Dilber E; Erduran E; Işik Y
Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of infantile visceral leishmaniasis].
Minodier P; Faraut-Gambarelli F; Piarroux R; Gire C; Garnier JM; Dumon H
Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
[TBL] [Abstract][Full Text] [Related]
8. Pediatric visceral leishmaniasis in southern France.
Minodier P; Piarroux R; Garnier JM; Unal D; Perrimond H; Dumon H
Pediatr Infect Dis J; 1998 Aug; 17(8):701-4. PubMed ID: 9726344
[TBL] [Abstract][Full Text] [Related]
9. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
10. [Visceral leishmaniasis: new drugs].
Minodier P; Robert S; Retornaz K; Garnier JM
Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
[TBL] [Abstract][Full Text] [Related]
11. [Successful treatment of cutaneous leishmaniasis with amphotericin B; a case of unresponsive to pentavalent antimony therapy].
Yeşilova Y; Turan E; Sürücü HA; Aksoy M; Özbilgin A
Turkiye Parazitol Derg; 2015 Mar; 39(1):63-5. PubMed ID: 25917587
[TBL] [Abstract][Full Text] [Related]
12. Treatment of leishmaniasis in HIV-positive patients.
Laguna F
Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():135-42. PubMed ID: 14678640
[TBL] [Abstract][Full Text] [Related]
13. Drug regimens for visceral leishmaniasis in Mediterranean countries.
Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
Minodier P; Retornaz K; Horelt A; Garnier JM
Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
[TBL] [Abstract][Full Text] [Related]
15. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.
Badaro R; Falcoff E; Badaro FS; Carvalho EM; Pedral-Sampaio D; Barral A; Carvalho JS; Barral-Netto M; Brandely M; Silva L
N Engl J Med; 1990 Jan; 322(1):16-21. PubMed ID: 2104665
[TBL] [Abstract][Full Text] [Related]
16. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
Thakur CP; Thakur S; Narayan S; Sinha A
Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
[TBL] [Abstract][Full Text] [Related]
18. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Mediterranean visceral leishmaniasis.
Gradoni L; Bryceson A; Desjeux P
Bull World Health Organ; 1995; 73(2):191-7. PubMed ID: 7743590
[TBL] [Abstract][Full Text] [Related]
20. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK
Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
